Design, Setting, and Participants
HIE, Encephalopathy, Asphyxia, hypothermia
SECONDARY, ENCEPHALOPATHY, ASPHYXIA
This study is a preplanned secondary analysis of prospectively collected data from infants enrolled in the High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial, which tested the efficacy of erythropoietin as an adjunctive neuroprotective therapy to therapeutic hypothermia. The study was conducted at 17 academic sites comprising 23 neonatal intensive care units in the United States between January 25, 2017, and October 9, 2019, with follow-up through October 2022. Overall, 500 infants born at 36 weeks’ gestation or later with moderate or severe HIE were included.